Biotech | August 10, 2021
INNOVIO QoQ revenues down for the period ended June 30, 2021
Company working on COVID vaccine INO 4800
Company working on COVID vaccine INO 4800
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
Subscribe To Our Newsletter & Stay Updated
